Spiriva® Assessment of FEV1 (SAFE)
Pulmonary Disease, Chronic Obstructive
About this trial
This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive
Eligibility Criteria
Inclusion Criteria: Diagnosis of COPD Stable airway obstruction FEV1 < or equal to 65% of predicted Male or female Age > or equal to 40 years > or equal to 10 pack year smoking history History of exacerbations in the past year Able to be trained in the proper use of the HandiHaler® Exclusion Criteria: History of asthma Allergic rhinitis or atopy Unstable use (6 weeks) of OCS (or > 10 mg daily use) History of life threatening bronchial obstruction, cystic fibrosis or bronchiectasis Patients who had started or stopped an exercise rehabilitation program in the past twelve months Thoracotomy with pulmonary resection or lobectomy (LVRS) Active tuberculosis Use of beta-blockers Pregnant, nursing women and women of childbearing potential not using a medically approved means of contraception 6 months or less history of myocardial infarction Intolerance to anticholinergic containing products, and/or to lactose or any other components of the inhalation capsule delivery system History of unstable arrhythmia with a life threatening event or change of related therapy during the past year History of cancer, other than treated basal cell carcinoma, within the last 12 months Clinically relevant abnormal baseline haematology, blood chemistry or urinalysis Patients with narrow angle glaucoma Patients with symptomatic benign prostatic hypertrophy Patients with bladder neck obstruction Patients that planned to be out of the country for 8 weeks or more
Sites / Locations
- Respiratory Research, Room 1742
- Boehringer Ingelheim Investigational Site
- 4A-185, 7007-14 Street SW
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 301-131 First Ave.
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 220 Royal Avenue
- Penticton Regional Hospital
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 1095 Concordia Avenue
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 262 Newfoundland Drive
- 300 Prince Philip Drive
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 169 Main Street East
- 237 Barton Street East
- HGH McMaster Clinic
- Boehringer Ingelheim Investigational Site
- 50 Charlton Avenue East
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Haemolology Division
- St Joseph's Healthcare
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 300-2338 Hurontario Street
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Ottawa Hospital - General Campus
- 1053 Carling Avenue
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 825 Coxwell Avenue
- Boehringer Ingelheim Investigational Site
- 600 Sherbourne Street, Suite 402
- Boehringer Ingelheim Investigational Site
- Toronto General Hospital
- 76 Grenville Street
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 91 Thomas-Chapais
- 305 rue Saint-Vallier
- Boehringer Ingelheim Investigational Site
- 4 rue Robinson
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 2180 rue Fleury E
- UHRESS, Pavillon L-C Simard, 10th Floor, Z10904
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Hop du Sacre-Coeur de Montreal
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 3001 12e ave Nord
- Boehringer Ingelheim Investigational Site
- Hopital Laval
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- Boehringer Ingelheim Investigational Site
- 1401-18 Rue